<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02526953</url>
  </required_header>
  <id_info>
    <org_study_id>SCAC-001</org_study_id>
    <nct_id>NCT02526953</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients</brief_title>
  <official_title>Randomised Phase III Trial of Chemoradiotherapy With or Without Paclitaxel in Patients With Squamous-cell Anal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Blokhin's Russian Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Blokhin's Russian Cancer Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the combination of paclitaxel,
      capecitabine, mitomycin and intensity-modulated radiotherapy is more effective than the
      standard combination of capecitabine, mitomycin and intensity-modulated radiotherapy (IMRT)
      in patients with squamous-cell anal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial aims to investigate the efficacy of chemoradiotherapy with or without paclitaxel
      in squamous-cell anal cancer. This is a prospective multicenter open-label randomized phase
      III clinical trial. Patients will be randomized using an online randomization system to
      receive either standard IMRT with capecitabine and mitomycin or IMRT with capecitabine,
      mitomycin and paclitaxel. A stratification will be performed based on T stage, N stage and
      clinical center. Doses of capecitabine and mitomycin in experimental group were reduced for
      better treatment tolerance. The target accrual is 157 patients in each treatment arm
      (including 10% potential data loss) based on potential benefit of 15% 3-yr disease-free
      survival (70% vs 85%), α=0,05, power 80% in the experimental arm. An interim analysis is
      planned after 50% of the patients will reach a 3-year followup. Pelvic Magnetic Resonance
      Imaging (MRI) is performed in all patients for staging and followup. Pelvic MRI and
      histological diagnosis are subject to central review. Conduction of this study and data
      collection are controlled by a local institutional board.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-year disease-free survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete response at 26 weeks</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year colostomy-free survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year cancer-specific survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year overall survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute toxicity measured according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v.4.0</measure>
    <time_frame>30 days</time_frame>
    <description>Toxicity measured according to NCI-CTCAE v.4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late toxicity measured according to Radiation Therapy Oncology Group (RTOG) criteria</measure>
    <time_frame>3 years</time_frame>
    <description>Late toxicity measured according to RTOG criteria</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Quality of life according to European organization for research and treatment of cancer (EORTC) Quality of Life questionnaire (QLQ)-C30 (v.3) scale</measure>
    <time_frame>3 years</time_frame>
    <description>Change from baseline in quality of life on the EORTC QLQ-C30 (v.3) scale</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">314</enrollment>
  <condition>Anus Neoplasms</condition>
  <condition>Carcinoma, Squamous Cell</condition>
  <condition>Anus Diseases</condition>
  <condition>Neoplasms</condition>
  <condition>Neoplasms, Squamous Cell</condition>
  <condition>Carcinoma</condition>
  <arm_group>
    <arm_group_label>Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive intensity-modulated radiotherapy with dose based on T stage. The planned doses to the primary tumor and pelvis are 52-58 Gy and 44 Gy, respectively.The concurrent chemotherapy regimen will consist of paclitaxel 45 mg/m2 on days 3,10,17,24,31, capecitabine 625 mg/m2 bid on treatment days and mitomycin C 10 g/m2 on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive intensity-modulated radiotherapy with dose based on T stage. The planned doses to the primary tumor and pelvis are 52-58 Gy and 44 Gy, respectively.The concurrent chemotherapy regimen will consist of capecitabine 825 mg/m2 bid on treatment days and mitomycin C 12 g/m2 on day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>45 mg/m2, IV, weekly during the radiation. Number of infusions: 5.</description>
    <arm_group_label>Paclitaxel</arm_group_label>
    <other_name>(2α,4α,5β,7β,10β,13α)-4,10-bis(acetyloxy)-13-{[(2R,3S)- 3-(benzoylamino)-2-hydroxy-3-phenylpropanoyl]oxy}- 1,7-dihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>625 mg/m2, bid, per os, only on days of radiation (Monday through Friday)</description>
    <arm_group_label>Paclitaxel</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)</description>
    <arm_group_label>Standard</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitomycins</intervention_name>
    <description>10 mg/m2, IV, on day 1. Number of infusions: 1.</description>
    <arm_group_label>Paclitaxel</arm_group_label>
    <other_name>Mitomycin C</other_name>
    <other_name>MMC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitomycins</intervention_name>
    <description>12 mg/m2, IV, on day 1. Number of infusions: 1.</description>
    <arm_group_label>Standard</arm_group_label>
    <other_name>Mitomycin C</other_name>
    <other_name>MMC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Dose: 44 Gy on regional nodes, 52-58 Gy on primary tumor, based on T stage</description>
    <arm_group_label>Paclitaxel</arm_group_label>
    <arm_group_label>Standard</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent

          -  Histologically verified squamous-cell anal cancer

          -  Stage I-IIIB (Union for International Cancer Control (UICC) TNM classification v7)

          -  Eastern Cooperative Oncology Group (ECOG) status 0-2

          -  HIV (Human Immunodeficiency Virus) negative

          -  Haemoglobin (HGB) &gt; 90 g/L

          -  Platelet Count (PLT) &gt; 120x10*9/L

          -  Serum creatinine &lt; 150 µmol/L

          -  Total bilirubin &lt; 25 µmol/L

        Exclusion Criteria:

          -  inability to obtain informed consent

          -  distant metastases

          -  synchronous or metachronous tumors

          -  previous chemotherapy or radiotherapy

          -  clinically significant cardiovascular disorders (myocardial infarction &lt; 6 months
             before visit, stroke &lt; &lt; 6 months before visit, instable angina &lt; 3 months before
             visit, arrhythmia, uncontrolled hypertension &gt; 160/100 mm hg

          -  clinically significant neurological disorders

          -  previous neuropathy 2 or higher

          -  current infection or heavy systemic disease

          -  pregnancy, breastfeeding

          -  ulcerative colitis

          -  individual intolerance to treatment components

          -  proven dihydropyrimidine dehydrogenase (DPD) deficiency

          -  participation in other clinical trials

          -  psychiatric disorders, which render patient unable to follow instructions or
             understand his/her condition

          -  technical inability to perform pelvic MRI

          -  inability of long-term followup of the patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arsen O Rasulov, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>N.N.Blokhin Russian Cancer Research Center</affiliation>
  </overall_official>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2015</study_first_submitted>
  <study_first_submitted_qc>August 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2015</study_first_posted>
  <last_update_submitted>June 8, 2017</last_update_submitted>
  <last_update_submitted_qc>June 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Blokhin's Russian Cancer Research Center</investigator_affiliation>
    <investigator_full_name>Sergey Gordeyev</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>anal cancer</keyword>
  <keyword>chemoradiation</keyword>
  <keyword>intensity-modulated radiotherapy</keyword>
  <keyword>paclitaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Anus Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Squamous Cell</mesh_term>
    <mesh_term>Anus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

